Highest-materiality recent filing
CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative
Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.
CV Sciences shareholders reject reverse stock split; three directors elected
Proposal 2 (reverse stock split up to 1-for-800) failed: 48.5M for, 59.6M against, 8.1M abstain.
CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M
Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.
CV Sciences issues $99,614 senior secured convertible note; conversion price cut to $0.03
Issued $99,614.04 senior secured convertible note due July 6, 2027 to an institutional investor.
CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M
Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.
CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M
Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.
Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.
CV Sciences issues $600K secured note with $300K net proceeds; potential add'l $750K
Issued $600K secured promissory note with 25% OID ($150K) plus $150K modification fee; net proceeds $300K.
CV Sciences amends $1.6M secured note, extends maturity to 2027, defers payments
Original $1.6M note issued Feb 2025 with $400K OID; outstanding balance $1.28M after $320K payments.
CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years
Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.
Quorum of 54.6% (100.7M of 184.3M shares); directors Corroon, Dowling, McCorkle elected with 17.0M-32.9M votes for.
CV Sciences Q1 2025 revenue $3.6M (-10% YoY); turns operating profit $11K
Q1 revenue $3.6M vs $4.0M YoY; unit volume down 11.8%, partially offset by 0.9% price increase.
CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023
Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).
CV Sciences issues $1.6M secured promissory note, net proceeds $1.2M
Principal $1.6M with $400K original issue discount, net $1.2M to company.
CV Sciences initiates arbitration against former legal counsel Procopio over faulty RSU tax advice
Arbitration filed Feb 12, 2025; claims Procopio provided incorrect tax advice on CEO Mona's RSU settlement.
CV Sciences disputes Extract Labs acquisition termination by Sellers; evaluating options
On Feb 5, 2025, Extract Labs owners informed CV Sciences they cannot close due to alleged failure to obtain bank consent, purportedly terminating the Stock Purchase Agreement.
CV Sciences prevails in arbitration against former executive Michael Mona Jr.
On Nov 20, 2024, arbitrator ruled in favor of CV Sciences and management, denying all claims by Mona.
CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout
Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.
CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k
Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.
Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.
CV Sciences enters $1.19M secured note with Streeterville Capital, net proceeds $900K
Principal amount $1,188,500; net proceeds $900,000 after $283,500 OID and $5,000 fees.
CV Sciences enters new 3-year employment agreements with CEO and CFO
CEO Joseph Dowling new base salary $300K/year, target annual bonus 50% of base.
CV Sciences stockholders elect directors, ratify auditor, approve exec comp at 2024 annual meeting
Quorum of 53.1% achieved with 86,682,380 shares represented at June 3, 2024 meeting.
CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production
Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.
CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M
Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.
CV Sciences FY2023 revenue $16.0M (flat), gross margin improves to 44.3% from 34.2%
Revenue $16.0M for FY2023, flat vs $16.2M in 2022; Q4 revenue $3.8M down 2% YoY.
CV Sciences acquires Cultured Foods for up to $535K to enter plant-based food market
Total consideration up to $535K: $175K cash, 7.07M shares valued at $250K, plus up to $110K earn-out.
CV Sciences Q3 revenue $4.1M (+9% YoY); margin expands; signs LOI for European acquisition
Revenue $4.1M, +9% YoY from $3.8M; gross margin 45.1% vs 41.6%.
CV Sciences Q2 revenue $4.0M; gross margin 43.3%, operating loss narrows to $1.1M
Revenue of $4.0M, down 4% YoY from $4.1M; units sold down 16%, offset by higher average selling price.
CV Sciences shareholders approve 2023 Equity Incentive Plan, elect directors
Stockholders approved 2023 Equity Incentive Plan (11.7M for, 8.6M against) to replace 2013 Plan.
CV Sciences Q1 revenue down 7% to $4.1M; gross margin improves to 43% vs 26% YoY
Revenue $4.1M vs $4.4M YoY; sequential increase of 7% from Q4 2022.
CV Sciences FY2022 revenue $16.2M, down 19% YoY; operating loss narrows to $6.8M
Revenue $16.2M for FY2022 vs $20.0M in 2021 (-19%); Q4 revenue $3.9M, up 3% sequentially.
U.S. District Court for Nevada granted preliminary approval on Feb 7, 2023 for settlement of Lamont v. Mona, Jr. (Case 2:15-cv-00481).
CV Sciences Q3 2022 revenue down 27% YoY to $3.8M, operating loss narrowed to $0.9M
Revenue $3.8M, down 27% from $5.1M; gross margin 41.6% vs 46.2%.
CV Sciences appoints William McCorkle as director and Audit Committee chair
William McCorkle appointed to Board on Oct 21, 2022; will serve as Chair of Audit Committee.
CV Sciences reaches preliminary settlement of six derivative lawsuits; court grants approval
Court granted preliminary approval on Sept 21, 2022; final hearing set for Nov 14, 2022.
CV Sciences issues $2M secured note, extinguishes convertible debt to reduce dilution
Entered $2M secured promissory note with Streeterville Capital; net proceeds $1.59M after $400K OID and $10K fees.
CV Sciences Q2 2022 revenue falls 19% to $4.1M; gross margin drops to 30.7%
Revenue $4.1M down from $5.1M YoY; units sold decreased 5%.
CV Sciences appoints Dr. Jamie Corroon Jr. to board; Dr. Maroon resigns
Dr. Jamie Corroon Jr. appointed to Board of Directors effective July 21, 2022.
CV Sciences resolves note default via conversion; investor converts $152K into 3.75M shares at $0.04
CV Sciences failed to repay $130K principal plus interest on Nov 2021 senior convertible note at May 17, 2022 maturity, causing default.
CV Sciences stockholders approve 4x share increase, reverse split up to 1:400; Board reduced to 3
Stockholders elected Dr. Joseph Maroon and Joseph Dowling as directors; 3 prior directors did not stand for re-election.
CV Sciences defaults on $1.06M convertible note; enters forbearance until June 1, 2022
Failed to pay $130K principal plus interest on May 17, 2022 maturity date, triggering default.
CV Sciences Q1 revenue $4.4M (-8% YoY); operating loss narrows to $1.5M on ERC benefit
Revenue $4.4M, down 8% from $4.8M in Q1 2021; units shipped up 3% offset by discounts and mix.
CV Sciences raises $700K via convertible preferred and warrants; seeks reverse split up to 1:400
Issued 700 shares of convertible preferred ($1,000 stated value) convertible into 10M shares at $0.07/sh, plus warrants for 10M shares at $0.10/sh.
CV Sciences reports FY2021 revenue down 18% to $20.0M; loss narrows to $18.4M
Revenue of $20.0M for FY2021, down 18% from $24.4M in 2020.
CV Sciences closes second tranche of $1.06M convertible note issuance, netting ~$950K
Second closing of $1.06M senior convertible notes (6% OID) under existing SPA, net proceeds ~$950K.
Term through Dec 26, 2024; Base salary $350K, reduced to $235K plus deferred comp accrual.
CV Sciences amends 8-K to correct Deloitte & Touche letter error in Exhibit 16.1
Amendment replaces Exhibit 16.1 due to an error in the Deloitte & Touche LLP letter originally filed on Nov 30, 2021.
CV Sciences dismisses Deloitte, appoints Haskell & White as new auditor to reduce costs
Dismissed Deloitte & Touche and engaged Haskell & White as independent auditor effective November 30, 2021.
CV Sciences Q3 2021 revenue down 8% to $5.1M; cash drops to $1.7M
Revenue $5.1M vs $5.6M YoY (-8%); operating loss $3.0M vs $3.2M.
On October 21, 2022, the Board of Directors of CV Sciences, Inc. (the "Company") appointed William McCorkle as a director on the Company’s Board of Directors (the “Board”).
On July 21, 2022, Dr. Joseph C. Maroon resigned as a member of the Board of Directors of the Company.
On July 21, 2022, the Board of Directors of CV Sciences, Inc. (the "Company") appointed Dr. Jamie Corroon Jr., ND, MPH as a director on the Company’s Board of Directors (the “Board”).
On September 24, 2021, Dr. Douglas MacKay submitted his resignation from his position as CV Sciences, Inc.'s Senior Vice President, Scientific and Regulatory Affairs.
Max materiality 0.75 · Median 0.60 · Most common event earnings